Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: A survival meta-analysis of randomized controlled trials

BACKGROUND: Monoclonal antibodies such as rituximab (RTX), eculizumab, inebilizumab, satralizumab, and tocilizumab have been found to be effective therapies for neuromyelitis optica spectrum disease ​(NMOSD) in several clinical randomized controlled trials. OBJECTIVE: The purpose of this meta-analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xintong, Xie, Lindan, Wei, Lili, Li, Meixuan, Wang, Hao, Zhou, Huanfen, Sun, Mingming, Yang, Mo, Xu, Quangang, Yang, Kehu, Wei, Shihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577852/
https://www.ncbi.nlm.nih.gov/pubmed/37846287
http://dx.doi.org/10.1016/j.aopr.2022.100064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577852/
https://www.ncbi.nlm.nih.gov/pubmed/37846287
http://dx.doi.org/10.1016/j.aopr.2022.100064

Ejemplares similares